This website is intended for residents of Australia
Choose your country
By clicking a link below you are choosing to leave the BioMarin Australia website; the country chosen is responsible for the content on that website.
About BioMarin Australia

Our Motivation

Patients are our purpose. Science is our passion.

A message from our Managing Director

Image of Dr Kathryn Evans

Pioneers in Rare Disease

Established in 2012, BioMarin Pharmaceutical Australia Pty Ltd brings first- or best-in-class therapies for patients living with rare genetic diseases. Our culture revolves around the ethos that no disease should go untreated, and our people are driven to discover, develop, and commercialise medicines that give patients, their families, and their caregivers hope where there was little or none.

Recent Milestones

VOXZOGO® was registered in the Australian Register of Therapeutic Goods (ARTG) from 30 June, 2022 and we have applied to the Pharmaceutical Benefits Advisory Committee (PBAC) for listing on the Pharmaceutical Benefits Scheme (PBS). We have also applied in 2022 for PBS listing of PALYNZIQ®, which was included in the ARTG from 14 July, 2021.

Development Programs

We have multiple sites in Australia involved in our global clinical trial programs, including for treatments for achondroplasia, severe haemophilia A, phenylketonuria (PKU), and hereditary angioedema (HAE).

Focus on Diversity

BioMarin is committed to cultivating a diverse, equitable and inclusive community for our employees. We are focused on our most important asset, our people, to ensure we are the premier place to work and that our people can bring their best selves to work. More diverse and inclusive workforces drive financial outcomes; employee investment in work; creativity; and innovation, which supports BioMarin to make a difference for more people with rare diseases. BioMarin is proud to be named a “Best Place to Work for LGBTQ Equality” in 2021.

Stewards of the Environment

It is up to all of us to protect our planet. As global citizens, we strive to operate in a way that protects the environment and provides a safe and healthful workplace for personnel and the communities that we serve.

Rare opportunities. Personal impact

Our employees feel connected to their work at BioMarin because they believe in our purpose: the patient. The passion and dedication that our employees bring to work each day is a testament to the inspiration patients living with rare diseases provide, and our knowledge of the impact we can make. Our appetite for science drives us. Our team members motivate us. And our patients inspire us. Together we’re growing a company unlike any other, because our motivation is unlike any other.

Our focus on rare disease gives us the rare opportunity to truly impact lives.

Dr Kathryn Evans
Managing Director, BioMarin Pharmaceutical Australia Pty Ltd
Area Director, Australia and New Zealand

25 February 2022

Find out more at BioMarin.com

Image of BioMarin building

Our history

Our journey of fighting rare diseases started in 1997, at a time when the treatment of rare disease was still rare. With a relentless commitment to helping patients battle rare genetic diseases, BioMarin is resolved to overcome the biggest scientific challenges and has made numerous breakthroughs in developing innovative therapies for rare disease patients to achieve the optimal outcomes.

Read more about our history on BioMarin.com

BioMarin logo

At a glance

BioMarin Pharmaceutical Australia Pty Ltd

Location: 119 Willoughby Rd, Crows Nest, NSW 2065
Phone: 02 9967 8662
Email: anz@bmrn.com
Founded: 2012

Managing Director: Kathryn Evans
Employees: 8
Focus: Rare genetic diseases

Products included in Australian Register of Therapeutic Goods (ARTG):

  • Brineura® (cerliponase alfa) for the treatment of neuronal ceroid lipofuscinosis type 2 (CLN2) disease, also known as tripeptidyl peptidase 1 (TPP1) deficiency.
  • Kuvan® (sapropterin dihydrochloride) Tablets for Oral Use and Powder for Oral Solution for the treatment of hyperphenylalaninemia (HPA) by reducing blood phenylalanine levels in patients with phenylketonuria (PKU) or tetrahydrobiopterin (BH4) deficiency.
  • PALYNZIQ® (pegvaliase) for the treatment of patients with phenylketonuria (PKU) whose blood phenylalanine levels cannot be adequately controlled by other means such as by diet.
  • NAGLAZYME® (galsulfase (rch)) for the treatment of Mucopolysaccharidosis VI (MPS VI) storage disorder, a disease in which the enzyme level of Nacetylgalactosamine 4-sulfatase is absent or lower than normal.
  • VIMIZIM® (elosulfase alfa (rch) for the treatment of MPS IVA (Mucopolysaccharidosis Type IVA, Morquio A Syndrome).
  • VOXZOGO® (vosoritide) for the treatment of achondroplasia in patients 2 years of age and older whose epiphyses are not closed. The diagnosis of achondroplasia should be confirmed by appropriate genetic testing.

Development Programs

Treatments for children with achondroplasia, severe haemophilia A, phenylketonuria (PKU), and hereditary angioedema (HAE).

Parent company: BioMarin Pharmaceutical Inc